Event
Spring Event 2021: The direct effect of COVID-19 on the Pharmaceutical landscape – now and downstream
Virtual Event - via Zoom
Thursday 25 February 2021, 15.00-18.00
Full BHBIA members can now view videos of the following sessions:
- The Effect of COVID-19 on the Market Access Landscape - Carolyn Chamberlain - Commercial Director, Blueprint Partnership and Mark Waker - Managing Director, MTW Consultancy
- Panel Discussion: Janneke van den Bent - Manager, SKIM, Carolyn Chamberlain and Mark Waker, chaired by Board members Kate Stevens and Rob Heathcote
You will need to log in to access these - once logged in, the links and passwords will appear on the page below this text.
You can also download the slides - again a link will appear when you log in.
Overview
This meeting explored the insights from one on one interviews with Payers, conducted over December 2020 and January 2021, from across both the EU5 and US.
Speakers explored key pertinent, ‘hot off the press’ topics which will affect the entire Healthcare industry, namely:
- How have budgets been affected and what are the implications for new drug approvals?
- Which, if any therapy areas, are ‘true’ losers – i.e. cancer care? What about mental health?
- Are there any ‘winners’?
- What does this mean for new products coming to market?
- What does this mean for best practice Pharma insights?
Sadly, it really is the ‘perfect storm’ – tightening of healthcare budgets, increases in the level of chronic illness and the economic crisis are all placing immense strain on healthcare services around the world.
We focused on uncovering the reality and impact of COVID 19 and the implications on the pharma industry, BI and ultimately patients!
This meeting is for anyone involved with Pharma Market Research, Insight and Analytics wanting to understand the impact of COVID-19 on the pharma landscape
The presentation was followed by a panel discussion and Q&A session to dive into the detail and reflect on the insights as a BI community.
Provisional Programme
3:00pm: Meeting open and welcome
Conveners: BHBIA Board Directors: Kate Stevens - KES Consultancy and Rob Heathcote - IQVIA
Introduction of agenda, speakers and housekeeping
3:10pm: The direct effect of COVID - 19 on the Pharmaceutical landscape – now and downstream
Carolyn Chamberlain - Commercial Director, Blueprint Partnership and Mark Waker - Managing Director, MTW Consultancy
3:35pm: Break
3:45pm: Panel Discussion:
Panel: Janneke van den Bent - Manager, SKIM, Carolyn Chamberlain and Mark Waker
Hear
our speakers and panellists discuss their experiences and opinions on
key takeaways from the main paper:
- New medicine approvals/HTA’s/Market Access landscape
- Telehealth
- Impact on face to face interactions – patients, HCPs, Pharma & BI
4:15pm: Break
4:25pm: Q&A to panel
Take the opportunity to pose your questions to the panel and open the discussion to the wider BI community
4:45pm: The BOBI Mini Challenge 2021:
The business part of the event will be followed by an optional social/networking event with a twist, run by BOBI Committee members Steve North - i2i (insight 2 implement), Wilf Iliffe - 14 Four Analytics, Alison Buchanan - Alison Buchanan Associates and Mariam Mansoor, Independent Consultant
The
BOBI Mini-Challenge is based broadly on the successful BOBI Challenge format
but in an online format.
- Teams will be asked to evaluate a business opportunity and make recommendations to the Leadership team of a fictitious Biotech company. Although this is a simulation, the challenges are based on business issues you may come across in the real world, in a safe, fun and energising environment. The product under discussion is a fictitious treatment for 'Long Covid' so it's highly topical.
- Can you engage successfully as a virtual team and spot the opportunities and potential pitfalls in the business case?
- How would you like to be the winner of the first BOBI Mini-Challenge?
By 6.00pm: Close
Speaker details:
(see also the Speaker Biographies link on the right for photos)
With a track record of more than 20+ years of experience in pharmaceutical market research, both client and agency side, working in a variety of roles.
Her career began at AstraZeneca Global where she led insights teams within CV and Oncology for over a decade. Her contributions helped drive the growth of key blockbusters. Carolyn is a well-known commercial market leader in qualitative and quantitative insight in both the UK and overseas. She is passionate about engaging with a diverse range of stakeholders and driving debate in our industry. We must continue to positively disrupt and transform our industry!
Over the last 15 years, she has held
senior commercial and leadership positions whilst also being a key contributor
to EphMRA, PMRC and the BHBIA.
Mark is managing director of a market access consultancy, MTW Consultancy Ltd, specialising in advising small to medium sized pharmaceutical companies as well as governments on integrated pricing, reimbursement, access and health economic solutions to healthcare delivery. Mark has over twenty years’ industry experience working in a broad range of therapeutic areas with exposure to all stages of the product life cycle. Working with payers and market access stakeholders, projects undertaken range from early asset pipeline assessments through to LOE and life-cycle management access strategies. Mark also specialises in advising companies on how to optimally integrate and structure market access capabilities within their organisations.
Mark started off his career at Procter & Gamble then held marketing and market access roles at Merck and Nycomed before setting up his own consultancy in 2010.
Janneke is a manager at SKIM with an educational background in Anthropology and Business Administration. She has one big regret in life: Not choosing to study medicine instead. Healthcare market research is thus the perfect intersection of her interests & her educational background.
Through the years, she’s come to realize that her heart lies in patient research and she’s been a part of many patient experience studies using both traditional and novel research methodologies across indications.